Clinical Trials on Neisseria Meningitidis Infection in New Zealand

Total 6779 results

University of Adelaide

Completed

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults (AMEND)

Meningococcal Infections | Neisseria Infection | Neisseria Meningitis Sepsis

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

Meningitis | Neisseria Meningitidis | Meningococcemia

United States
GlaxoSmithKline

Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
Enanta Pharmaceuticals, Inc

Terminated

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Chronic Hepatitis B Virus Infection

New Zealand
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Australia, Mexico
Capital and Coast District Health board
Wellington Southern Community Laboratories; Institute of Environmental Science...

Recruiting

Evaluation of a mNGS Workflow for Infection Diagnosis Using Oxford Nanopore Sequencing.

Bacterial Infections

New Zealand
John Hale

Recruiting

Antiviral Activity of Oral Probiotics

Lower Respiratory Tract Infection | Upper Respiratory Tract Infection

New Zealand
Gilead Sciences

Completed

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

HCV Infection

New Zealand
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Hepatitis C Virus Infection

New Zealand
Gilead Sciences

Completed

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Chronic Hepatitis C Infection

New Zealand
NeuMoDx Molecular, Inc.
NAMSA

Completed

NeuMoDx PrEDiCTiNG Study Evaluation Plan

Neisseria Gonorrheae Infection | Chlamydia Trachomatis Infection

United States
AmtixBio Co., Ltd.
Novotech (Australia) Pty Limited

Completed

A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

Onychomycosis

New Zealand
AmtixBio Co., Ltd.

Not yet recruiting

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

Onychomycosis

New Zealand
Pfizer

Completed

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (B1971042)

Meningitis, Meningococcal, Serogroup B

United States
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
Valneva Austria GmbH

Completed

VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

SARS-CoV-2 Infection

New Zealand, Netherlands
Kirby Institute
Griffith University

Active, not recruiting

Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men (GoGoVax)

Neisseria Gonorrheae Infection

Australia
Pfizer

Completed

An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Duke University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT (pNAAT)

Sexually Transmitted Infections | Chlamydia Trachomatis Infection | Neisseria Gonorrhoeae Infection

United States
Gen-Probe, Incorporated

Completed

Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System

Chlamydia Trachomatis | Neisseria Gonorrhoeae Infection

United States
Sanofi

Completed

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

Meningococcal Infections | Meningococcal Meningitis

United States
Pfizer

Completed

Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
National Institute of Allergy and Infectious Diseases...

Completed

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
Syneos Health
F-star Therapeutics, Inc.

Completed

A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection

Hepatitis C Infection

Australia, New Zealand
All India Institute of Medical Sciences, New Delhi

Recruiting

Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes

Tuberculous Meningitis | Tuberculous Arachnoiditis

India
Pfizer

Completed

Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
Enanta Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Completed

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Hepatitis C

New Zealand
University of Auckland, New Zealand

Completed

The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination

Vaccination

New Zealand
Ellume Pty Ltd

Withdrawn

Performance of Ellume·Lab Group A Strep Test Versus Culture for the Rapid Detection of Group A Streptococcus in Participants With Acute Pharyngitis

Group A Streptococcal Infection

New Zealand
Akesobio Australia Pty Ltd

Completed

A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

Coronavirus Disease 2019 (COVID-19)

New Zealand
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients

Chronic Hepatitis b

New Zealand
National Institute of Allergy and Infectious Diseases...

Completed

Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis

Cryptococcal Meningitis

United States, Thailand
Hoffmann-La Roche

Completed

A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic, Healthy Volunteer

New Zealand
Sanofi

Completed

A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India

Meningitis | Meningococcal Infection

India
Arrow Therapeutics

Completed

Antiviral Activity of AZD7295 in HCV Carriers

Hepatitis C

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Hepatitis C

New Zealand
Alios Biopharma Inc.

Completed

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Hepatitis B

New Zealand
Vaxart

Completed

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Seasonal Influenza B

New Zealand
Assembly Biosciences

Not yet recruiting

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes

Recurrent Genital Herpes Simplex Type 2

New Zealand
Murdoch Childrens Research Institute

Recruiting

BonE and Joint Infections - Simplifying Treatment in Children Trial (BEST)

Osteomyelitis | Septic Arthritis | Bone Infection | Bone and Joint Infection

New Zealand, Australia
Gilead Sciences

Completed

Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

Chronic Hepatitis B

New Zealand
Soroka University Medical Center
Eiger BioPharmaceuticals

Active, not recruiting

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection (LOWR6)

Hepatitis D, Chronic

Israel, New Zealand, Turkey
Assembly Biosciences

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults

Chronic Hepatitis B

New Zealand
InterMune

Completed

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States, Peru

3

Subscribe